Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Abeona Therapeutics (ABEO) Net Income towards Common Stockholders: 2011-2024

Historic Net Income towards Common Stockholders for Abeona Therapeutics (ABEO) over the last 13 years, with Dec 2024 value amounting to -$63.7 million.

  • Abeona Therapeutics' Net Income towards Common Stockholders rose 82.95% to -$5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.2 million, marking a year-over-year increase of 194.92%. This contributed to the annual value of -$63.7 million for FY2024, which is 17.53% down from last year.
  • According to the latest figures from FY2024, Abeona Therapeutics' Net Income towards Common Stockholders is -$63.7 million, which was down 17.53% from -$54.2 million recorded in FY2023.
  • Abeona Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$43.5 million during FY2022, with a 5-year trough of -$84.9 million in FY2021.
  • For the 3-year period, Abeona Therapeutics' Net Income towards Common Stockholders averaged around -$53.8 million, with its median value being -$54.2 million (2023).
  • In the last 5 years, Abeona Therapeutics' Net Income towards Common Stockholders skyrocketed by 48.78% in 2022 and then dropped by 24.60% in 2023.
  • Abeona Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$84.2 million in 2020, then fell by 0.83% to -$84.9 million in 2021, then spiked by 48.78% to -$43.5 million in 2022, then dropped by 24.60% to -$54.2 million in 2023, then decreased by 17.53% to -$63.7 million in 2024.